The Role of p53 in Suppression of KSHV Cyclin-induced Lymphomagenesis

Emmy W. Verschuren, J. Graeme Hodgson, Joe Gray, Scott Kogan, Nic Jones, Gerard I. Evan

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a cyclin D homolog, K cyclin, that is thought to promote viral oncogenesis. However, expression of K cyclin in cultured cells not only triggers cell cycle pro-gression but also engages the p53 tumor suppressor pathway, which probably restricts the oncogenic potential of K cyclin. Therefore, to assess the tumorigenic properties of K cyclin in vivo, we transgenically targeted expression of K cyclin to the B and T lymphocyte compartments via the Eμ promoter/enhancer. Around 17% of Eμ-K cyclin animals develop lymphoma by 9 months of age, and all such lymphomas exhibit loss of p53. A critical role of p53 in suppressing K cyclin-induced lymphomagenesis was confirmed by the greatly accelerated onset of B and T lymphomagenesis in all Eμ-K cyclin/p53-/- mice. However, absence of p53 did not appear to accelerate K cyclin-induced lymphomagenesis by averting apoptosis: Eμ-K cyclin/p53-/- end-stage lymphomas contained abundant apoptotic cells, and transgenic Eμ-K cyclin/p53-/- lymphocytes in vitro were not measurably protected from DNA damage-induced apoptosis compared with Eμ-K cyclin/p53wt cells. Notably, whereas aneuploidy was frequently evident in pre-lymphomatous tissues, end-stage Eμ-K cyclin/p53-/- tumors showed a near-diploid DNA content with no aberrant centrosome numbers. Nonetheless, such tumor cells did harbor more restricted genomic alterations, such as single-copy chromosome losses or gains or high-level amplifications. Together, our data support a model in which K cyclin-induced genome instability arises early in the pre-tumorigenic lymphocyte population and that loss of p53 licenses subsequent expansion of tumorigenic clones.

Original languageEnglish (US)
Pages (from-to)581-589
Number of pages9
JournalCancer Research
Volume64
Issue number2
DOIs
StatePublished - Jan 15 2004
Externally publishedYes

Fingerprint

Human Herpesvirus 8
Cyclins
Cyclin E
Lymphoma
Cyclin T
Lymphocytes
Apoptosis
Cyclin D
Cyclin B
Neoplasms
Centrosome
Genomic Instability
Aneuploidy
Licensure
Diploidy
DNA Damage
Cultured Cells
Cell Cycle
Carcinogenesis
B-Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Verschuren, E. W., Hodgson, J. G., Gray, J., Kogan, S., Jones, N., & Evan, G. I. (2004). The Role of p53 in Suppression of KSHV Cyclin-induced Lymphomagenesis. Cancer Research, 64(2), 581-589. https://doi.org/10.1158/0008-5472.CAN-03-1863

The Role of p53 in Suppression of KSHV Cyclin-induced Lymphomagenesis. / Verschuren, Emmy W.; Hodgson, J. Graeme; Gray, Joe; Kogan, Scott; Jones, Nic; Evan, Gerard I.

In: Cancer Research, Vol. 64, No. 2, 15.01.2004, p. 581-589.

Research output: Contribution to journalArticle

Verschuren, EW, Hodgson, JG, Gray, J, Kogan, S, Jones, N & Evan, GI 2004, 'The Role of p53 in Suppression of KSHV Cyclin-induced Lymphomagenesis', Cancer Research, vol. 64, no. 2, pp. 581-589. https://doi.org/10.1158/0008-5472.CAN-03-1863
Verschuren, Emmy W. ; Hodgson, J. Graeme ; Gray, Joe ; Kogan, Scott ; Jones, Nic ; Evan, Gerard I. / The Role of p53 in Suppression of KSHV Cyclin-induced Lymphomagenesis. In: Cancer Research. 2004 ; Vol. 64, No. 2. pp. 581-589.
@article{bafe8a2547fd4b20b78f8075dfdc19ae,
title = "The Role of p53 in Suppression of KSHV Cyclin-induced Lymphomagenesis",
abstract = "Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a cyclin D homolog, K cyclin, that is thought to promote viral oncogenesis. However, expression of K cyclin in cultured cells not only triggers cell cycle pro-gression but also engages the p53 tumor suppressor pathway, which probably restricts the oncogenic potential of K cyclin. Therefore, to assess the tumorigenic properties of K cyclin in vivo, we transgenically targeted expression of K cyclin to the B and T lymphocyte compartments via the Eμ promoter/enhancer. Around 17{\%} of Eμ-K cyclin animals develop lymphoma by 9 months of age, and all such lymphomas exhibit loss of p53. A critical role of p53 in suppressing K cyclin-induced lymphomagenesis was confirmed by the greatly accelerated onset of B and T lymphomagenesis in all Eμ-K cyclin/p53-/- mice. However, absence of p53 did not appear to accelerate K cyclin-induced lymphomagenesis by averting apoptosis: Eμ-K cyclin/p53-/- end-stage lymphomas contained abundant apoptotic cells, and transgenic Eμ-K cyclin/p53-/- lymphocytes in vitro were not measurably protected from DNA damage-induced apoptosis compared with Eμ-K cyclin/p53wt cells. Notably, whereas aneuploidy was frequently evident in pre-lymphomatous tissues, end-stage Eμ-K cyclin/p53-/- tumors showed a near-diploid DNA content with no aberrant centrosome numbers. Nonetheless, such tumor cells did harbor more restricted genomic alterations, such as single-copy chromosome losses or gains or high-level amplifications. Together, our data support a model in which K cyclin-induced genome instability arises early in the pre-tumorigenic lymphocyte population and that loss of p53 licenses subsequent expansion of tumorigenic clones.",
author = "Verschuren, {Emmy W.} and Hodgson, {J. Graeme} and Joe Gray and Scott Kogan and Nic Jones and Evan, {Gerard I.}",
year = "2004",
month = "1",
day = "15",
doi = "10.1158/0008-5472.CAN-03-1863",
language = "English (US)",
volume = "64",
pages = "581--589",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - The Role of p53 in Suppression of KSHV Cyclin-induced Lymphomagenesis

AU - Verschuren, Emmy W.

AU - Hodgson, J. Graeme

AU - Gray, Joe

AU - Kogan, Scott

AU - Jones, Nic

AU - Evan, Gerard I.

PY - 2004/1/15

Y1 - 2004/1/15

N2 - Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a cyclin D homolog, K cyclin, that is thought to promote viral oncogenesis. However, expression of K cyclin in cultured cells not only triggers cell cycle pro-gression but also engages the p53 tumor suppressor pathway, which probably restricts the oncogenic potential of K cyclin. Therefore, to assess the tumorigenic properties of K cyclin in vivo, we transgenically targeted expression of K cyclin to the B and T lymphocyte compartments via the Eμ promoter/enhancer. Around 17% of Eμ-K cyclin animals develop lymphoma by 9 months of age, and all such lymphomas exhibit loss of p53. A critical role of p53 in suppressing K cyclin-induced lymphomagenesis was confirmed by the greatly accelerated onset of B and T lymphomagenesis in all Eμ-K cyclin/p53-/- mice. However, absence of p53 did not appear to accelerate K cyclin-induced lymphomagenesis by averting apoptosis: Eμ-K cyclin/p53-/- end-stage lymphomas contained abundant apoptotic cells, and transgenic Eμ-K cyclin/p53-/- lymphocytes in vitro were not measurably protected from DNA damage-induced apoptosis compared with Eμ-K cyclin/p53wt cells. Notably, whereas aneuploidy was frequently evident in pre-lymphomatous tissues, end-stage Eμ-K cyclin/p53-/- tumors showed a near-diploid DNA content with no aberrant centrosome numbers. Nonetheless, such tumor cells did harbor more restricted genomic alterations, such as single-copy chromosome losses or gains or high-level amplifications. Together, our data support a model in which K cyclin-induced genome instability arises early in the pre-tumorigenic lymphocyte population and that loss of p53 licenses subsequent expansion of tumorigenic clones.

AB - Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a cyclin D homolog, K cyclin, that is thought to promote viral oncogenesis. However, expression of K cyclin in cultured cells not only triggers cell cycle pro-gression but also engages the p53 tumor suppressor pathway, which probably restricts the oncogenic potential of K cyclin. Therefore, to assess the tumorigenic properties of K cyclin in vivo, we transgenically targeted expression of K cyclin to the B and T lymphocyte compartments via the Eμ promoter/enhancer. Around 17% of Eμ-K cyclin animals develop lymphoma by 9 months of age, and all such lymphomas exhibit loss of p53. A critical role of p53 in suppressing K cyclin-induced lymphomagenesis was confirmed by the greatly accelerated onset of B and T lymphomagenesis in all Eμ-K cyclin/p53-/- mice. However, absence of p53 did not appear to accelerate K cyclin-induced lymphomagenesis by averting apoptosis: Eμ-K cyclin/p53-/- end-stage lymphomas contained abundant apoptotic cells, and transgenic Eμ-K cyclin/p53-/- lymphocytes in vitro were not measurably protected from DNA damage-induced apoptosis compared with Eμ-K cyclin/p53wt cells. Notably, whereas aneuploidy was frequently evident in pre-lymphomatous tissues, end-stage Eμ-K cyclin/p53-/- tumors showed a near-diploid DNA content with no aberrant centrosome numbers. Nonetheless, such tumor cells did harbor more restricted genomic alterations, such as single-copy chromosome losses or gains or high-level amplifications. Together, our data support a model in which K cyclin-induced genome instability arises early in the pre-tumorigenic lymphocyte population and that loss of p53 licenses subsequent expansion of tumorigenic clones.

UR - http://www.scopus.com/inward/record.url?scp=1642556785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642556785&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-1863

DO - 10.1158/0008-5472.CAN-03-1863

M3 - Article

C2 - 14744772

AN - SCOPUS:1642556785

VL - 64

SP - 581

EP - 589

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 2

ER -